In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Open Access
- 1 March 2018
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (3)
Abstract
Candida auris is an emerging multidrug-resistant yeast that has been responsible for invasive infections associated with high morbidity and mortality. C. auris strains often demonstrate high fluconazole and amphotericin B MIC values, and some strains are resistant to all three major antifungal classes. We evaluated the susceptibility of 16 C. auris clinical strains, isolated from a wide geographical area, to 10 antifungal agents, including APX001A, a novel agent that inhibits the fungal protein Gwt1 (glycosylphosphatidylinositol-anchored wall transfer protein 1). APX001A demonstrated significantly lower MIC 50 and MIC 90 values (0.004 and 0.031 μg/ml, respectively) than all other agents tested. The efficacy of the prodrug APX001 was evaluated in an immunocompromised murine model of disseminated C. auris infection. Significant efficacy (80 to 100% survival) was observed in all three APX001 treatment groups versus 50% survival for the anidulafungin treatment group. In addition, APX001 showed a significant log reduction in CFU counts in kidney, lung, and brain tissue (1.03 to 1.83) versus the vehicle control. Anidulafungin also showed a significant log reduction in CFU in the kidneys and lungs (1.5 and 1.62, respectively) but did not impact brain CFU. These data support further clinical evaluation of this new antifungal agent.Keywords
This publication has 27 references indexed in Scilit:
- Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care SurfaceJournal of Clinical Microbiology, 2017
- Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission ofCandida aurisand OtherCandidaSpeciesInfection Control & Hospital Epidemiology, 2017
- Current perspective on emergence, diagnosis and drug resistance in Candida aurisInfection and Drug Resistance, 2017
- Investigation of the First Seven Reported Cases ofCandida auris,a Globally Emerging Invasive, Multidrug-Resistant Fungus — United States, May 2013–August 2016MMWR. Morbidity and Mortality Weekly Report, 2016
- Simultaneous Emergence of Multidrug-ResistantCandida aurison 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological AnalysesClinical Infectious Diseases, 2016
- First hospital outbreak of the globally emerging Candida auris in a European hospitalAntimicrobial Resistance & Infection Control, 2016
- Candida auris Candidemia in Kuwait, 2014Emerging Infectious Diseases, 2015
- Candida auris –Associated Candidemia, South AfricaEmerging Infectious Diseases, 2014
- E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol BiosynthesisAntimicrobial Agents and Chemotherapy, 2012
- Candida aurissp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospitalMicrobiology and Immunology, 2009